A New Era of Nuclear Medicine
Today you can see a huge difference from years ago in image quality, lesion detectability, and the impacts on diagnosis of patients.
Ronald Boellaard, PhD, University Medical Center Groningen
The culmination of innovation
Quantifying nuclear medicine
With xSPECT Quant, CHUV team members are able to quantify their SPECT/CT images.
In SPECT/CT, we can now precisely quantitate how much of the radiopharmaceutical we administer to the patient ends up in a given organ. Siemens Healthineers was the first one with this tool.
John Prior, PhD, MD, FEBNM; Centre Hospitalier Universitaire Vaudois
Delivering precision
There is a potential in better discriminating lesions from physiological background activity. And maybe upstaging your patients from, let’s say, uncertain up to the presence of a disease.
Walter Noordzij, PhD, MD; University Medical Center Groningen
Making a difference
The patient was scanned with a Biograph Vision, 1 hour 50 minutes post-injection delay. CT: 100 kV, 10 eff mAs., 32 x 1.2 mm collimation
PET: 7 beds, 3 minutes/bed, 440 x 440 matrix.
Data courtesy of UMCG, Groningen, The Netherlands.
Precision with Biograph Vision
Quantifying nuclear medicine with xSPECT Quant
The patient was scanned with a Symbia Intevo™ SPECT/CT, 170 mCi [6.3 GBq] 177Lu
DOTATATE; 2-, 24-, and 48-hour post-injection delay. CT: 130 kV, 30 mAs.
Data courtesy of CHUV, Lausanne, Switzerland.
- 1 Compared to current systems.
xSPECT Quant and Biograph Vision are not commercially available in some countries. Due to regulatory reasons, their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.